182 related articles for article (PubMed ID: 15126812)
1. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
McNeill SA; Hargreave TB;
J Urol; 2004 Jun; 171(6 Pt 1):2316-20. PubMed ID: 15126812
[TBL] [Abstract][Full Text] [Related]
2. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
McNeill SA; Hargreave TB; Roehrborn CG;
Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
[TBL] [Abstract][Full Text] [Related]
3. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Tiong HY; Tibung MJ; Macalalag M; Li MK; Consigliere D
Urol Int; 2009; 83(1):44-8. PubMed ID: 19641358
[TBL] [Abstract][Full Text] [Related]
4. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.
McNeill SA; Daruwala PD; Mitchell ID; Shearer MG; Hargreave TB
BJU Int; 1999 Oct; 84(6):622-7. PubMed ID: 10510105
[TBL] [Abstract][Full Text] [Related]
5. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
6. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Desgrandchamps F; De La Taille A; Doublet JD;
BJU Int; 2006 Apr; 97(4):727-33. PubMed ID: 16536763
[TBL] [Abstract][Full Text] [Related]
7. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F; Adjali K; Gomez Guerra L; Hong SJ; El Khalid S; Ratana-Olarn K;
BJU Int; 2012 Jan; 109(1):88-95. PubMed ID: 22117624
[TBL] [Abstract][Full Text] [Related]
8. The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis.
Annemans L; Cleemput I; Lamotte M; McNeill A; Hargreave T
BJU Int; 2005 Sep; 96(4):566-71. PubMed ID: 16104911
[TBL] [Abstract][Full Text] [Related]
9. Prostate size influences the outcome after presenting with acute urinary retention.
McNeill AS; Rizvi S; Byrne DJ
BJU Int; 2004 Sep; 94(4):559-62. PubMed ID: 15329112
[TBL] [Abstract][Full Text] [Related]
10. Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention.
Shah T; Palit V; Biyani S; Elmasry Y; Puri R; Flannigan GM
Eur Urol; 2002 Oct; 42(4):329-32; discussion 332. PubMed ID: 12361896
[TBL] [Abstract][Full Text] [Related]
11. Does acute urinary retention respond to alpha-blockers alone?
McNeill SA
Eur Urol; 2001 Mar; 39 Suppl 6():7-12. PubMed ID: 11306895
[TBL] [Abstract][Full Text] [Related]
12. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
[TBL] [Abstract][Full Text] [Related]
13. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
14. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
15. A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
Maldonado-Ávila M; Manzanilla-García HA; Sierra-Ramírez JA; Carrillo-Ruiz JD; González-Valle JC; Rosas-Nava E; Guzman-Esquivel J; Labra-Salgado IR
Int Urol Nephrol; 2014 Apr; 46(4):687-90. PubMed ID: 24061764
[TBL] [Abstract][Full Text] [Related]
16. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction.
Alan McNeill S
Eur Urol; 2004 Mar; 45(3):325-32. PubMed ID: 15036678
[TBL] [Abstract][Full Text] [Related]
17. Alpha blockers prior to removal of a catheter for acute urinary retention in adult men.
Zeif HJ; Subramonian K
Cochrane Database Syst Rev; 2009 Oct; (4):CD006744. PubMed ID: 19821385
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Roehrborn CG; Van Kerrebroeck P; Nordling J
BJU Int; 2003 Aug; 92(3):257-61. PubMed ID: 12887479
[TBL] [Abstract][Full Text] [Related]
19. Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia?
Kara O; Yazici M
Urol J; 2014 Jul; 11(3):1673-7. PubMed ID: 25015615
[TBL] [Abstract][Full Text] [Related]
20. The Reten-World survey of the management of acute urinary retention: preliminary results.
Emberton M; Fitzpatrick JM
BJU Int; 2008 Mar; 101 Suppl 3():27-32. PubMed ID: 18307683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
